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Resistance of Gram-positive pathogens to first-line antimicrobial agents has been increasing in many parts
of the world. We compared the in vitro activities of torezolid with those of other antimicrobial agents, including
linezolid, against clinical isolates of major aerobic and anaerobic bacteria. Torezolid had an MIC90 of <0.5
g/ml for the Gram-positive bacterial isolates tested and was more potent than either linezolid or vancomycin.
Antimicrobial resistance in Gram-positive cocci has become
a major problem in recent years. Oxazolidinones, a new ther-
apeutic class of synthetic drugs, are active against Gram-posi-
tive pathogens. Linezolid, the only marketed oxazolidinone,
inhibits the initiation of bacterial protein translation by binding
to the 23S rRNA peptidyl transferase region (15). The widely
used drug linezolid is effective against most Gram-positive
pathogens, including methicillin-resistant Staphylococcus au-
reus (MRSA), vancomycin-resistant Enterococcus spp., and
penicillin-resistant Streptococcus pneumoniae (1, 2). However,
several recent studies have reported the emergence of lin-
ezolid-resistant staphylococci and enterococci in Brazil, China,
France, Germany, Italy, and Sweden. The dominant resistance
mechanisms are mutations of the 23S rRNA gene and the
recently described mobile chloramphenicol-florfenicol resis-
tance (cfr) methyltransferase gene (9).
The antibacterial activity of oxazolidinones depends on their
affinity for the site of action on the ribosome. Therefore, by
modifying their chemical structure, novel oxazolidinones with
improved antimicrobial activity can be obtained. Accordingly,
it is important to find more useful and less toxic oxazolidino-
nes. Torezolid [TR-700, DA-7157; R-3-(4-(2-(2-methyltet-
razol-5-yl)pyridine-5-yl)-3-fluorophenyl)-5-hydroxymethyl ox-
azolidin-2-on] is the active moiety of the prodrug torezolid
phosphate (TR-701, DA-7218) (Fig. 1). In a recent study, tor-
ezolid was 4- to 8-fold more active than linezolid against Gram-
positive bacteria collected from the United States (3). In an-
other study, torezolid demonstrated an 8- to 16-fold increase in
potency against all of the linezolid-resistant isolates tested,
including MRSA, MRSA carrying the mobile cfr methyltrans-
ferase gene, and vancomycin-resistant enterococci (14). How-
ever, as far as we know, the activities of torezolid against
anaerobic bacteria have not been reported.
Human plasma protein binding of torezolid was about 80%
(data not shown), and the MIC was unaffected by the presence of
20% human plasma (4). Torezolid has a better pharmacokinetic
profile than linezolid. After oral administration of torezolid at 200
mg once a day, the maximum concentration of the drug in serum,
half-life, and area under the curve were 2.0g/ml, 11.2 h, and 25.4
g  h/ml, respectively (13). In another study, torezolid phosphate
was safe and effective with once-daily 200-mg dosing over 5 to 7
days of treatment for severe complicated skin and skin structure
infections caused by Gram-positive bacteria (16). In this study, we
compared the in vitro activities of torezolid with those of other
antimicrobial agents, including linezolid, against clinical isolates
of major aerobic and anaerobic Gram-positive and Gram-nega-
tive bacteria.
(Part of this study was presented at the 44th Interscience
Conference on Antimicrobial Agents and Chemotherapy,
Washington, DC, 2004 [12]).
Five hundred ten nonduplicate aerobic and anaerobic bac-
terial isolates were collected between 2002 and 2004 from
patients at a South Korean tertiary-care hospital. The species
were identified by conventional methods or by using either the
ID 32 GN or the ATB 32A system (bioMe´rieux, Marcy-
l’Etoile, France). Antimicrobial susceptibility was tested by the
CLSI agar dilution method (5, 6, 7). The media used were
Mueller-Hinton agar (Becton Dickinson, Sparks, MD) for test-
ing of Staphylococcus spp., Enterococcus spp., and Moraxella
catarrhalis; Mueller-Hinton agar supplemented with 5% sheep
blood for Streptococcus spp.; Haemophilus test medium for
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TABLE 1. Comparative antimicrobial activities of torezolid and other antimicrobial agents against aerobic and anaerobic bacteria
Organism (no. of isolates tested) and
antimicrobial agent
Breakpoint (g/ml)f MIC (g/ml) Susceptibility (%)f
S I R Range 50% 90% S I R
Methicillin-susceptible S. aureus (30)
Torezolid NAg NA NA 0.5–1 0.5 0.5 NA NA NA
Linezolid 4 8 2–4 4 4 100 NA 0
Erythromycin 0.5 1–4 8 0.5–128 0.5 128 63 7 30
Clindamycin 0.5 1–2 4 0.06–1 0.25 0.25 97 3 0
Cotrimoxazole 2/38 4/76 0.06–32 0.25 2 90 NA 10
Gentamicin 4 8 16 0.06–128 0.5 128 70 3 27
Levofloxacin 1 2 4 0.5–8 0.5 1 97 0 3
Tetracycline 4 8 16 0.25–64 0.5 32 83 0 17
Oxacillin 2 4 0.06–0.5 0.5 0.5 100 NA 0
Vancomycin 2 4–8 16 0.5–1 0.5 1 100 0 0
MRSA (30)
Torezolid NA NA NA 0.5 0.5 0.5 NA NA NA
Linezolid 4 8 2–4 2 4 100 NA 0
Erythromycin 0.5 1–4 8 0.5–128 128 128 3 3 93
Clindamycin 0.5 1–2 4 0.25–128 128 128 17 0 83
Cotrimoxazole 2/38 4/76 0.25–128 0.5 128 73 NA 27
Gentamicin 4 8 16 0.25–128 64 128 13 0 87
Levofloxacin 1 2 4 0.5–128 16 128 17 0 83
Tetracycline 4 8 16 0.5–128 64 64 33 0 67
Oxacillin 2 4 32–128 128 128 0 NA 100
Vancomycin 2 4–8 16 0.5–2 1 1 100 0 0
Methicillin-susceptible, coagulase
negative staphylococci (29)
Torezolid NA NA NA 0.25–0.5 0.5 0.5 NA NA NA
Linezolid 4 8 1–4 2 4 100 NA 0
Erythromycin 0.5 1–4 8 0.25–128 0.5 128 76 0 24
Clindamycin 0.5 1–2 4 0.12–128 0.25 1 90 7 3
Cotrimoxazole 2/38 4/76 0.06–32 0.25 16 90 NA 10
Gentamicin 4 8 16 0.06–128 0.12 64 69 7 24
Levofloxacin 1 2 4 0.25–32 0.5 0.5 97 0 3
Tetracycline 4 8 16 0.5–128 0.5 32 76 0 24
Oxacillin 0.25 0.5 0.06–0.25 0.12 0.25 100 NA 0
Vancomycin 2 4–8 16 0.5–2 1 1 100 0 0
Methicillin-resistant, coagulase
negative staphylococci (26)
Torezolid NA NA NA 0.12–0.5 0.5 0.5 NA NA NA
Linezolid 4 8 0.5–4 2 2 100 NA 0
Erythromycin 0.5 1–4 8 0.06–128 64 128 42 0 58
Clindamycin 0.5 1–2 4 0.12–128 0.25 128 62 0 38
Cotrimoxazole 2/38 4/76 0.06–32 2 32 50 NA 50
Gentamicin 4 8 16 0.06–128 16 64 27 15 58
Levofloxacin 1 2 4 0.12–16 0.5 16 73 12 15
Tetracycline 4 8 16 0.5–128 4 128 69 4 27
Oxacillin 0.25 0.5 0.5–128 4 64 0 NA 100
Vancomycin 2 4–8 16 0.25–2 1 2 100 0 0
Vancomycin-susceptible Enterococcus
faecalis (49)
Torezolid NA NA NA 0.12–0.5 0.25 0.5 NA NA NA
Linezolid 2 4 8 0.5–2 2 2 100 0 0
Ampicillin 8 16 0.25–8 1 4 100 NA 0
Erythromycin 0.5 1–4 8 0.12–128 4 128 9 42 49
Levofloxacin 2 4 8 0.5–64 2 64 69 0 31
Tetracycline 4 8 16 0.5–128 64 64 20 0 80
Vancomycin 4 8–16 32 1–4 2 2 100 0 0
Teicoplanin 8 16 32 0.12–0.5 0.25 0.5 100 0 0
Vancomycin-resistant E. faecalis (12)
Torezolid NA NA NA 0.25–0.5 0.25 0.5 NA NA NA
Linezolid 2 4 8 0.5–1 1 1 100 0 0
Ampicillin 8 16 1–4 2 4 100 NA 0
Erythromycin 0.5 1–4 8 128 128 128 0 0 100
Continued on following page
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TABLE 1—Continued
Organism (no. of isolates tested) and
antimicrobial agent
Breakpoint (g/ml)f MIC (g/ml) Susceptibility (%)f
S I R Range 50% 90% S I R
Levofloxacin 2 4 8 16–128 64 64 0 0 100
Tetracycline 4 8 16 0.5–64 32 64 8 0 92
Vancomycin 4 8–16 32 128 128 128 0 0 100
Teicoplanin 8 16 32 32–128 64 64 0 0 100
Vancomycin-susceptible Enterococcus
faecium (30)
Torezolid NA NA NA 0.06–0.25 0.25 0.25 NA NA NA
Linezolid 2 4 8 0.5–2 2 2 100 0 0
Ampicillin 8 16 1–128 128 128 7 NA 93
Erythromycin 0.5 1–4 8 0.25–128 128 128 3 7 90
Levofloxacin 2 4 8 2–128 64 64 3 7 90
Tetracycline 4 8 16 0.12–32 0.5 1 97 0 3
Vancomycin 4 8–16 32 0.5–4 0.5 0.5 100 0 0
Teicoplanin 8 16 32 0.25–2 0.5 0.5 100 0 0
Vancomycin-resistant E. faecium (29)
Torezolid NA NA NA 0.06–0.25 0.12 0.25 NA NA NA
Linezolid 2 4 8 0.5–1 1 1 100 0 0
Ampicillin 8 16 64–128 128 128 0 NA 100
Erythromycin 0.5 1–4 8 64–128 128 128 0 0 100
Levofloxacin 2 4 8 16–128 64 128 0 0 100
Tetracycline 4 8 16 0.06–128 0.25 128 90 0 10
Vancomycin 4 8–16 32 64–128 128 128 0 0 100
Teicoplanin 8 16 32 2–64 16 64 21 31 48
S. pneumoniae (29)
Torezolid NA NA NA 0.12–0.5 0.25 0.25 NA NA NA
Linezolid 2 0.5–2 1 1 100 NA NA
Penicillin G 0.06 0.12 0.015–2 1 2 17 NA 83
Cefotaximec 0.5 1 2 0.015–2 1 2 31 55 14
Clindamycin 0.25 0.5 1 0.25–128 128 128 28 0 72
Erythromycin 0.25 0.5 1 0.25–128 128 128 14 0 86
Cotrimoxazole 0.5/9.5 1/19–2/38 4/76 0.5–128 16 64 24 10 66
Levofloxacin 2 4 8 1–2 2 2 100 0 0
Tetracycline 2 4 8 0.12–32 16 32 10 0 90
S. pyogenes (15)
Torezolid NA NA NA 0.06–0.25 0.12 0.25 NA NA NA
Linezolid 2 1–2 1 2 100 NA NA
Penicillin G 0.12 0.008–0.015 0.015 0.015 100 NA NA
Cefotaxime 0.5 0.008–0.03 0.015 0.03 100 NA NA
Clindamycin 0.25 0.5 1 0.12–0.25 0.12 0.25 100 0 0
Erythromycin 0.25 0.5 1 0.12–0.25 0.12 0.25 100 0 0
Levofloxacin 2 4 8 0.5–4 1 4 80 20 0
S. agalactiae (15)
Torezolid NA NA NA 0.12–0.5 0.25 0.5 NA NA NA
Linezolid 2 1–2 2 2 100 NA NA
Penicillin G 0.12 0.03–0.06 0.06 0.06 100 NA NA
Cefotaxime 0.5 0.03–0.06 0.06 0.06 100 NA NA
Clindamycin 0.25 0.5 1 0.25–128 0.25 128 53 0 47
Erythromycin 0.25 0.5 1 0.25–128 0.5 128 13 47 40
Levofloxacin 2 4 8 1–2 1 2 100 0 0
M. catarrhalis (27)
Torezolid NA NA NA 0.5–2 1 1 NA NA NA
Linezolid NA NA NA 2–8 4 4 NA NA NA
Penicillin G NA NA NA 0.03–32 16 32 NA NA NA
Cefaclor 8 16 32 0.25–32 2 8 96 0 4
Clindamycin 0.5 1–2 4 1–4 2 4 0 59 41
Erythromycin 0.5 1–4 8 0.12–0.5 0.25 0.5 100 0 0
Levofloxacin 2 0.06 0.06 0.06 100 NA NA
Tetracycline 2 4 8 0.25–16 0.5 0.5 96 0 4
Continued on following page
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TABLE 1—Continued
Organism (no. of isolates tested) and
antimicrobial agent
Breakpoint (g/ml)f MIC (g/ml) Susceptibility (%)f
S I R Range 50% 90% S I R
H. influenzae (25)
Torezolid NA NA NA 2–16 2 4 NA NA NA
Linezolid NA NA NA 4–16 8 16 NA NA NA
Ampicillin 1 2 4 0.5–128 128 128 16 8 76
Ampicillin-sulbactam 2/1 4/2 0.5–8 4 8 36 NA 64
Cefaclor 8 16 32 2–128 4 128 60 0 40
Cefuroxime 4 8 16 0.25–128 1 128 80 4 16
Cefotaxime 2 0.008–0.5 0.03 0.5 100 NA NA
Azithromycin 4 2–4 4 4 100 NA NA
Cotrimoxazole 0.5/9.5 1/19–2/38 4/76 0.06–32 4 32 48 0 52
Levofloxacin 2 0.015–0.5 0.03 0.06 100 NA NA
Tetracycline 2 4 8 0.25–32 0.5 8 84 4 12
Peptostreptococcus spp. (59)a
Torezolid NA NA NA 0.03–0.25 0.06 0.25 NA NA NA
Linezolid NA NA NA 0.25–2 0.5 1 NA NA NA
Ampicillin 0.5 1 2 0.06–16 0.12 1 90 2 8
Ampicillin-sulbactam 8/4 16/8 32/16 0.06–8 0.12 1 100 0 0
Piperacillin 32 64 128 0.06–16 0.06 8 100 0 0
Piperacillin-tazobactam 32/4 64/4 128/4 0.06–16 0.06 8 100 0 0
Cefoxitin 16 32 64 0.06–16 0.25 4 100 0 0
Cefotetan 16 32 64 0.06–128 0.5 16 92 2 7
Imipenem 4 8 16 0.06–1 0.06 0.12 100 0 0
Clindamycin 2 4 8 0.06–128 0.5 64 80 0 20
Metronidazole 8 16 32 0.06–4 1 2 100 0 0
Vancomycin NA NA NA 0.12–1 0.25 0.5 NA NA NA
Clostridium perfringens (15)
Torezolid NA NA NA 0.12–0.25 0.25 0.25 NA NA NA
Linezolid NA NA NA 1–2 2 2 NA NA NA
Ampicillin 0.5 1 2 0.06–0.5 0.06 0.12 100 0 0
Ampicillin-sulbactam 8/4 16/8 32/16 0.06–0.5 0.06 0.25 100 0 0
Piperacillin 32 64 128 0.06–1 0.06 0.25 100 0 0
Piperacillin-tazobactam 32/4 64/4 128/4 0.06 0.06 0.06 100 0 0
Cefoxitin 16 32 64 0.25–1 0.5 1 100 0 0
Cefotetan 16 32 64 0.06–0.5 0.06 0.12 100 0 0
Imipenem 4 8 16 0.06–0.12 0.06 0.06 100 0 0
Clindamycin 2 4 8 0.06–2 1 2 100 0 0
Metronidazole 8 16 32 1–4 4 4 100 0 0
Vancomycin NA NA NA 0.5–2 0.5 0.5 NA NA NA
Other Clostridium spp. (15)b
Torezolid NA NA NA 0.06–0.25 0.25 0.25 NA NA NA
Linezolid NA NA NA 0.5–4 2 4 NA NA NA
Ampicillin 0.5 1 2 0.06–1 0.25 1 87 13 0
Ampicillin-sulbactam 8/4 16/8 32/16 0.06–2 0.25 1 100 0 0
Piperacillin 32 64 128 0.06–16 1 8 100 0 0
Piperacillin-tazobactam 32/4 64/4 128/4 0.06–16 1 8 100 0 0
Cefoxitin 16 32 64 0.25–128 8 64 60 0 40
Cefotetan 16 32 64 0.06–128 2 128 53 7 40
Imipenem 4 8 16 0.06–4 1 4 100 0 0
Clindamycin 2 4 8 0.06–128 1 128 53 13 33
Metronidazole 8 16 32 0.12–16 4 8 93 7 0
Vancomycin NA NA NA 0.25–8 4 8 NA NA NA
Other anaerobic Gram-positive
bacilli (13)c
Torezolid NA NA NA 0.06–0.5 0.06 0.5 NA NA NA
Linezolid NA NA NA 0.06–4 0.5 2 NA NA NA
Ampicillin 0.5 1 2 0.06–2 0.06 1 85 8 8
Ampicillin-sulbactam 8/4 16/8 32/16 0.06–2 0.12 1 100 0 0
Piperacillin 32 64 128 0.06–8 0.5 8 100 0 0
Piperacillin-tazobactam 32/4 64/4 128/4 0.06–8 0.06 8 100 0 0
Cefoxitin 16 32 64 0.06–128 1 128 100 0 0
Cefotetan 16 32 64 0.12–128 4 128 62 8 31
Imipenem 4 8 16 0.06–2 0.12 2 100 0 0
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TABLE 1—Continued
Organism (no. of isolates tested) and
antimicrobial agent
Breakpoint (g/ml)f MIC (g/ml) Susceptibility (%)f
S I R Range 50% 90% S I R
Clindamycin 2 4 8 0.06–4 0.06 2 92 8 0
Metronidazole 8 16 32 0.25–128 128 128 38 8 54
Vancomycin NA NA NA 0.25–32 0.5 32 NA NA NA
B. fragilis (30)
Torezolid NA NA NA 1–4 2 2 NA NA NA
Linezolid NA NA NA 2–4 4 4 NA NA NA
Ampicillin 0.5 1 2 16–128 32 128 0 0 100
Ampicillin-sulbactam 8/4 16/8 32/16 1–32 2 16 83 7 10
Piperacillin 32 64 128 4–256 32 256 53 17 30
Piperacillin-tazobactam 32/4 64/4 128/4 0.12–8 0.25 1 100 0 0
Cefoxitin 16 32 64 4–64 8 32 87 7 7
Cefotetan 16 32 64 4–128 8 32 83 7 10
Imipenem 4 8 16 0.06–4 0.25 1 100 0 0
Clindamycin 2 4 8 0.06–128 128 128 43 0 57
Metronidazole 8 16 32 0.5–8 4 4 100 0 0
B. thetaiotaomicron (15)
Torezolid NA NA NA 1–2 2 2 NA NA NA
Linezolid NA NA NA 4 4 4 NA NA NA
Ampicillin 0.5 1 2 16–128 32 128 0 0 100
Ampicillin-sulbactam 8/4 16/8 32/16 1–32 1 32 73 13 13
Piperacillin 32 64 128 16–256 32 256 73 0 27
Piperacillin-tazobactam 32/4 64/4 128/4 2–16 4 8 100 0 0
Cefoxitin 16 32 64 16–32 16 32 73 27 0
Cefotetan 16 32 64 32–128 128 128 0 13 87
Imipenem 4 8 16 0.12–2 0.25 2 100 0 0
Clindamycin 2 4 8 2–128 8 128 7 40 53
Metronidazole 8 16 32 2–4 4 4 100 0 0
Other Bacteroides spp. (14)d
Torezolid NA NA NA 1–4 1 2 NA NA NA
Linezolid NA NA NA 1–4 2 4 NA NA NA
Ampicillin 0.5 1 2 2–128 128 128 0 0 100
Ampicillin-sulbactam 8/4 16/8 32/16 1–32 8 32 57 29 14
Piperacillin 32 64 128 2–256 64 256 43 14 43
Piperacillin-tazobactam 32/4 64/4 128/4 2–16 4 8 100 0 0
Cefoxitin 16 32 64 4–64 16 32 79. 14 7
Cefotetan 16 32 64 4–128 64 128 29 14 57
Imipenem 4 8 16 0.06–2 0.5 1 100 0 0
Clindamycin 2 4 8 4–128 128 128 0 7 93
Metronidazole 8 16 32 0.25–4 4 4 100 0 0
Other anaerobic Gram-negative rods
(27)e
Torezolid NA NA NA 0.03–4 0.25 2 NA NA NA
Linezolid NA NA NA 0.12–8 1 4 NA NA NA
Ampicillin 0.5 1 2 0.03–128 1 64 22 33 44
Ampicillin-sulbactam 8/4 16/8 32/16 0.03–4 1 4 100 0 0
Piperacillin 32 64 128 0.06–128 4 32 93 4 4
Piperacillin-tazobactam 32/4 64/4 128/4 0.06–8 0.06 4 100 0 0
Cefoxitin 16 32 64 0.06–8 1 4 100 0 0
Cefotetan 16 32 64 0.06–32 2 16 93 7 0
Imipenem 4 8 16 0.06–1 0.06 1 100 0 0
Clindamycin 2 4 8 0.06–128 0.06 64 78 7 15
Metronidazole 8 16 32 0.06–4 0.5 4 100 0 0
Chloramphenicol 8 16 32 0.5–8 2 4 100 0 0
a Finegoldia magna (19 strains), Peptoniphilus asaccharolyticus (15 strains), Peptostreptococcus anaerobius (12 strains), Peptostreptococcus micros (7 strains), and
Anaerococcus prevotii (6 strains).
b Clostridium clostridiiforme (3 strains), C. sordellii (1 strain), C. innocuum (5 strains), C. tertium (2 strains), C. ramosum (2 strains), C. sporogenes (1 strain), and C.
bifermentans (1 strain).
c Bifidobacterium adolescentis (2 strains), Propionibacterium acnes (4 strains), Eubacterium lentum (3 strains), Lactobacillus acidophilus (2 strains), and Actinomyces
sp. (2 strains).
d Bacteroides distasonis (5 strains), B. vulgatus (7 strains), and B. ovatus (2 strains).
e Prevotella bivia (6 strains), P. buccae (3 strains), P. intermedia (4 strains), P. oralis (2 strains), Fusobacterium mortiferum (3 strains), F. necrophorum (2 strains), F.
varium (6 strains), and Fusobacterium sp. (1 strain).
f S, susceptible; I, intermediate; R, resistant.
g NA, not applicable.
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Haemophilus influenzae; and brucella agar (Becton Dickinson)
supplemented with 5 g hemin, 1 g vitamin K1 per ml, and
5% laked sheep blood for anaerobic bacteria.
The antimicrobial agents used were torezolid and linezolid
(Dong-A, Seoul, South Korea); erythromycin, tetracycline, ox-
acillin, penicillin G, and cefuroxime (Sigma Chemical, St.
Louis, MO); piperacillin and tazobactam (Yuhan, Seoul, South
Korea); azithromycin and sulbactam (Pfizer Korea, Seoul,
South Korea); clindamycin (Korea Upjohn, Seoul, South Ko-
rea); levofloxacin (Daiichi, Tokyo, Japan); ampicillin, genta-
micin, and chloramphenicol (Chong Kun Dang, Seoul, South
Korea); cefotaxime (Han-Dok, Seoul, South Korea); cefoxitin
and imipenem (Merck Sharp & Dohme, Rahway, NJ); ce-
fotetan (Je Il, Seoul, South Korea); metronidazole (Choong
Wae, Seoul, South Korea); trimethoprim and sulfamethox-
azole (Dong Wha, Seoul, South Korea); cefaclor and vanco-
mycin (Daewoong, Seoul, South Korea); and teicoplanin
(Sanofi Aventis, Bridgewater, NJ).
American Type Culture Collection strains of S. aureus (ATCC
29213), Enterococcus faecalis (ATCC 29212), S. pneumoniae
(ATCC 49619), H. influenzae (ATCC 49247), Bacteroides fragilis
(ATCC 25285), and Bacteroides thetaiotaomicron (ATCC 29741)
were used as reference strains. The meningeal breakpoints of
penicillin G and cefotaxime were used for S. pneumoniae.
MRSA continues to be prevalent in South Korea, accounting
for 64% of the S. aureus strains in one study (10). In this study, all
of the isolates of staphylococci tested were inhibited by torezolid
at 1 g/ml and the MIC for 90% of the strains tested (MIC90)
was 4- to 8-fold lower than that of linezolid (Table 1). The ma-
jority of the MRSA isolates was resistant to erythromycin, clin-
damycin, gentamicin, levofloxacin, and tetracycline.
Vancomycin-resistant Enterococcus faecium has become
prevalent in the United States (18). The vancomycin resistance
rate of E. faecium has been 20% or higher in South Korean
hospitals since 2003 (10). The MIC ranges of torezolid were
0.06 to 0.25 g/ml for all of the enterococci, including vanco-
mycin-resistant ones, while those of linezolid were 0.5 to 2
g/ml (Table 1), which are similar to prior reports (8, 17). All
of the isolates were susceptible to linezolid.
Penicillin-nonsusceptible S. pneumoniae strains were very prev-
alent (69%) in South Korean hospitals in 2007, when the menin-
geal breakpoint was applied. In this study, most of the pneumo-
coccal isolates tested were nonsusceptible to penicillin G or
cefotaxime, but the MIC range of torezolid was 0.12 to 0.5 g/ml
and the MIC90 was 4-fold lower than that of linezolid (Table 1).
All of the isolates of Streptococcus pyogenes and Streptococcus
agalactiae were inhibited by torezolid at 0.5 g/ml.
-Lactamase-producing M. catarrhalis and H. influenzae
were prevalent in South Korea (11). The MIC ranges of tor-
ezolid for M. catarrhalis and H. influenzae were 0.5 to 2 and 2
to 16 g/ml, respectively. The MIC90s for both of these organ-
isms were 4-fold lower than those of linezolid.
Intraabdominal and soft-tissue infections are often due to
aerobic and anaerobic bacteria. Torezolid had excellent activ-
ity against Gram-positive anaerobes (Table 1). All of the pep-
tostreptococci and anaerobic Gram-positive bacilli were inhib-
ited by torezolid at 0.5 g/ml, and the MIC90s for these
organisms were 4- to 16-fold lower than those of linezolid. The
MIC90 of torezolid, 2 g/ml, for anaerobic Gram-negative ba-
cilli, was slightly lower than that of linezolid, 4 g/ml (Table 1).
In conclusion, torezolid is a new antimicrobial agent with
high in vitro activity against common aerobic and anaerobic
Gram-positive bacteria, including multidrug-resistant isolates.
Further studies are warranted to determine the clinical utility
of torezolid as a therapeutic agent.
We are grateful to Young Hee Suh for technical assistance.
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